Boehringer Ingelheim Ulm University BioCenter (BIU)
On October 19, 2011 Prof. Dr. Gerd Schnorrenberg, Senior Vice President of Boehringer Research Germany and Prof. Dr. Karl Joachim Ebeling, at that time President Ulm University, signed the co-operation agreement of the "Public-Private-Partnership-Research Association BIU" in the presence of Theresia Bauer, Minister of Research of the State of Baden-Wuerttemberg, and Prof. Dr. Dr. Andreas Barner, Speaker of the Boehringer Ingelheim management.
The research focuses on neuropsychiatric, cardio metabolic and lung diseases as well as immunmodulatory aspects. The goals of the newly founded research association are the identification and characterization of new biomarkers, the analysis of misregulated signaling pathways as well as establishing new innovative preclinical and clinical concepts in translational research. The BioCenter is founded according to the structures and criteria of the well-established collaborative research centers of the German Research Foundation (DFG). The BIU research consortium is established for a period of 8 years and was positively evaluated after 3 years. Since April 1, 2016 the BioCenter is supported for additional 3 years with 4.5 Million Euros by Boehringer Ingelheim, the State of Baden-Wuerttemberg and the Medical Faculty of Ulm University.
The multidisciplinary research of the scientists at the Medical Faculty deals with neuropsychiatric diseases focusing on misdirected neuronal networks (circuits) as biological causes for neuropsychiatric symptom domains, e. g. cognition, impulsiveness, anhedonia or fear. That research includes topics such as epigenetic embossing of traumatic stressors, mechanisms of synaptic plasticity and cortical disinhibition.
The modulation of the immune system is gaining in importance as a fundamental biological principle in the pathogenesis of a large number of diseases. In order to use the underlying biological principles for a better understanding of disease, the newly established research field focuses on the identification and research of regulatory checkpoints in the immune response.